EXOTHERA
Une procédure de faillite est ouverte pour EXOTHERA selon les publications au Moniteur belge. Aucun chiffre de comptes annuels traité n'est disponible ; cette conclusion repose uniquement sur les données du registre et du Moniteur belge.
| Active | 6 ans |
| Sites | 5 |
| Publications | 21 |
Faillite ouverte
Une procédure de faillite est déjà en cours — un score de probabilité n'a plus de sens. Consultez la chronologie d'insolvabilité pour l'état de la procédure.
| Exercice | Type | Dépôt | Référence |
|---|---|---|---|
| 31-12-2023 | volledig | 04-07-2024 | 2024-00231646 |
| 31-12-2022 | volledig | 11-07-2023 | 2023-00224470 |
| 31-12-2021 | volledig | 22-07-2022 | 2022-20225935 |
| 31-12-2020 | volledig | 18-06-2021 | 2021-22900004 |
| Rôle | Nom | Période | Source |
|---|---|---|---|
| Curateur | KARL DE RIDDER RUE DU PARC,49, 6000 CHAR-
LEROI |
26-08-2025 → auj. | Moniteur belge |
| Curateur | ISABELLE BRONKAERT CHAUSSEE
DE THUIN 164, 6032 MONT-SUR-MARCHIENNE-
.
Date provisoire de cessation de paiement : 26/08/2025 |
26-08-2025 → auj. | Moniteur belge |
| NACE primaire | 21201 |
| Forme juridique | SA(014) |
| Date de constitution | 02-03-2020 |
| Status | Actif |
| Code postal | 6040 |
| Premier signal MB | 02-09-2025 |
| Dernier signal MB | 02-09-2025 |
Parcelles liées à cette entreprise via ses adresses BCE (siège, unités d'établissement, succursales), croisées avec le plan parcellaire cadastral. Ceci montre où l'entreprise est active — pas un registre de propriété.
| Parcelle (capakey) | Région | Superficie | Bâtiments | Hauteur / ét. |
|---|---|---|---|---|
| 52034B1039/00Z004 | Wallonie | 9 994 m² | 1 · 3 265 m² | 11,1 m · 3 ét. |
| 52028B0323/00M003 | Wallonie | 8 679 m² | 1 · 791 m² | 18,8 m · 5 ét. |
| 21332B0081/00H002 | Bruxelles | 3 929 m² | 1 · 1 150 m² | 30,4 m · 9 ét. |
| 25099D0025/00L003 | Wallonie | 3 517 m² | 1 · 1 386 m² | 7,0 m · 2 ét. |
Une seule chronologie de tout ce qui est arrivé à cette entreprise — publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
27-01-2025 Augmentation de capital de 32.073.042 € à 42.326.984 €
- €10.253.942 → €42.326.984
- Inbreng in natura · Apport en nature
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 42326984,
"delta_eur": 32073042,
"before_eur": 10253942,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}27-01-2025 Augmentation de capital de 32.073.042 € à 42.326.984 €
- €10.253.942 → €42.326.984
- Inbreng in natura · Apport en nature
- 2 kapitaalbewegingen in deze akte
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 42326984.0,
"delta_eur": 32073042.0,
"before_eur": 10253942.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 32073042,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "natura",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 11068051.0,
"delta_eur": -31258933.0,
"before_eur": 42326984.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "vzw_capital_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": 11068051.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
}
],
"notary": {
"name": "Dimitri CLEENEWERCK de CRAYENCOUR",
"firm_city": null,
"firm_name": "DE CRAYENCOUR",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2025-01-27",
"filing_date": "2025-01-23",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2024-12-30",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "Deloitte R\u00E9viseurs d\u2019Entreprises SRL",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "Julie Delforge"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition conforme de l\u0027acte",
"procuration",
"Rapport du conseil d\u0027administration",
"Rapport du commissaire",
"statuts coordonn\u00E9s"
],
"shareholders_after": [],
"share_classes_after": []
}22-02-2024 Augmentation de capital de 2.000.000 € à 20.887.562 €
- €18.887.562 → €20.887.562
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 20887562,
"delta_eur": 2000000,
"before_eur": 18887562,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}22-02-2024 Réduction de capital de 10.633.620 € à 10.253.942 €
- €20.887.562 → €10.253.942
- 2 kapitaalbewegingen in deze akte
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 20887562.0,
"delta_eur": 2000000.0,
"before_eur": 18887562.0,
"subscribers": [
{
"kbo": "0502.742.288",
"rrn": null,
"kind": "org",
"name": "UNIVERCELLS",
"share_class": null,
"liberation_pct": 25.0,
"contribution_kind": "geld",
"n_shares_subscribed": 2000000,
"contribution_amount_eur": 2000000.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 2000000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 1.0
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 500000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": 1500000.0,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 10253942.0,
"delta_eur": -10633620.0,
"before_eur": 20887562.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0664.691.906",
"rrn": null,
"kind": "org",
"name": "BioPharma Management and Consulting",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Denis Bedoret",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0480.028.848",
"rrn": null,
"kind": "org",
"name": "SAMANDA SA",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Christine Franssen",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0884.085.417",
"rrn": null,
"kind": "org",
"name": "Cahn Consult BV",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Christel Dewitte",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0647.570.713",
"rrn": null,
"kind": "org",
"name": "TheClubDeal Capital Advisors",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Jean-Marc Legrand",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0809.766.886",
"rrn": null,
"kind": "org",
"name": "Alerion BV",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "David Louvet",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0675.690.518",
"rrn": null,
"kind": "org",
"name": "Viva Finance SRL",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Vincent Vanderborght",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Dimitri CLEENEWERCK de CRAYENCOUR",
"firm_city": null,
"firm_name": "DE CRAYENCOUR",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "mixed",
"pub_date": "2024-02-22",
"filing_date": "2024-02-20",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2023-12-22",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": "2023-12-18"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition conforme de l\u0027acte",
"procuration",
"proc\u00E8s-verbal sous seing priv\u00E9",
"statuts coordonn\u00E9s"
],
"shareholders_after": [],
"share_classes_after": []
}22-02-2024 2 administrateurs nommés, 4 démissionnaires
- Alerion BV — Bestuurder
- Viva Finance SRL — Bestuurder
- BioPharma Management and Consulting — Bestuurder
- SAMANDA SA — Bestuurder
- Cahn Consult BV — Bestuurder
- TheClubDeal Capital Advisors — Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "BioPharma Management and Consulting",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "SAMANDA SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Cahn Consult BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "TheClubDeal Capital Advisors",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Alerion BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Viva Finance SRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}18-09-2023 Deloitte Réviseur d'Entreprises nommé auditor
- Deloitte Réviseur d'Entreprises — Auditor
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "Deloitte R\u00E9viseur d\u0027Entreprises",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "Exothera"
}
}12-09-2023 Augmentation de capital de 10.000.000 € à 18.025.715 €
- €8.025.715 → €18.025.715
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 18025715.0,
"delta_eur": 10000000.0,
"before_eur": 8025715.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}12-09-2023 Augmentation de capital de 19.775.118 € à 37.800.833 €
- €18.025.715 → €37.800.833
- Inbreng in natura · Apport en nature
- 3 kapitaalbewegingen in deze akte
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 18025715.0,
"delta_eur": 10000000.0,
"before_eur": 8025715.0,
"subscribers": [
{
"kbo": "0744.643.660",
"rrn": null,
"kind": "org",
"name": "EXOTHERA",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 10000000,
"contribution_amount_eur": 10000000.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 10000000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 1.0
},
"decrease_purpose": null,
"contribution_type": "numeraire",
"paid_up_delta_eur": 10000000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 37800833.0,
"delta_eur": 19775118.0,
"before_eur": 18025715.0,
"subscribers": [
{
"kbo": "0744.643.660",
"rrn": null,
"kind": "org",
"name": "EXOTHERA",
"share_class": null,
"liberation_pct": null,
"contribution_kind": "schuldvordering",
"n_shares_subscribed": 19775118,
"contribution_amount_eur": 19775118.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 19775118,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "natura",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": 19775118,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 18887562.0,
"delta_eur": -18913271.0,
"before_eur": 37800833.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": 18887562.0,
"delta_eur": null,
"before_eur": 18887562.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
}
],
"notary": {
"name": "Dimitri CLEENEWERCK de CRAYENCOUR",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2023-09-12",
"filing_date": "2023-09-08",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2023-08-25",
"unanimous": true,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "Deloitte R\u00E9viseurs d\u2019Entreprises SRL",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "Julie Delforge"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition conforme de l\u0027acte",
"procuration",
"Rapport de l\u2019organe d\u0027administration",
"Rapport du commissaire",
"statuts coordonn\u00E9s"
],
"shareholders_after": [
{
"kbo": "0744.643.660",
"pct": null,
"kind": "org",
"name": "EXOTHERA",
"role": "aandeelhouder",
"n_shares": 70783958,
"share_class": null
}
],
"share_classes_after": []
}22-11-2022 Augmentation de capital de 23.000.000 € à 27.885.941 €
- €4.885.941 → €27.885.941
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 27885941.0,
"delta_eur": 23000000.0,
"before_eur": 4885941.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}22-11-2022 Augmentation de capital de 23.000.000 € à 27.885.941 €
- €4.885.941 → €27.885.941
- Inbreng in geld · Apport en numéraire
- 2 kapitaalbewegingen in deze akte
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 27885941.0,
"delta_eur": 23000000.0,
"before_eur": 4885941.0,
"subscribers": [
{
"kbo": "0744.643.660",
"rrn": null,
"kind": "org",
"name": "EXOTHERA",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 23000000,
"contribution_amount_eur": 23000000.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 23000000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 1.0
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 23000000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 8025715.0,
"delta_eur": -19860226.0,
"before_eur": 27885941.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 41008840,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Dimitri CLEENEWERCK de CRAYENCOUR",
"firm_city": null,
"firm_name": "G\u00E9rard INDEKEU - Dimitri CLEENEWERCK de CRAYENCOUR",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-11-22",
"filing_date": "2022-11-18",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2022-11-04",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": "2022-11-04"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition conforme de l\u0027acte",
"procuration",
"statuts coordonn\u00E9s"
],
"shareholders_after": [
{
"kbo": "0744.643.660",
"pct": null,
"kind": "org",
"name": "EXOTHERA",
"role": "aandeelhouder",
"n_shares": 41008840,
"share_class": null
}
],
"share_classes_after": []
}15-12-2021 Augmentation de capital de 10.000.000 € à 14.216.405 €
- €4.216.405 → €14.216.405
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 14216405.0,
"delta_eur": 10000000.0,
"before_eur": 4216405.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}11-08-2021 ANTROBUS nommé administrateur
- ANTROBUS — Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "ANTROBUS",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}30-06-2021 Thibault Jonckheere nommé délégué à la gestion journalière
- Thibault Jonckheere — Dagelijks bestuur
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Thibault Jonckheere",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}15-03-2021 Transfert du siège social de Nivelles à Jumet
- Rue de la Maitrise 11 à 1400 Nivelles → Allée Centrale, 52 à 6040 Jumet (Région wallonne)
Détails techniques
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "All\u00E9e Centrale, 52 \u00E0 6040 Jumet (R\u00E9gion wallonne)",
"city": "Jumet",
"region": "waals_gewest",
"street": "All\u00E9e Centrale",
"country": "BE",
"postcode": "6040",
"box_number": null,
"street_number": "52",
"locality_suffix": null
},
"old_address": {
"raw": "Rue de la Maitrise 11 \u00E0 1400 Nivelles",
"city": "Nivelles",
"region": "waals_gewest",
"street": "Rue de la Maitrise",
"country": "BE",
"postcode": "1400",
"box_number": null,
"street_number": "11",
"locality_suffix": null
},
"effective_date": "2020-12-21",
"evidence_quote": "Aux termes du pro\u00E7\u00E8s-verbal du conseil d\u0027administration de la soci\u00E9t\u00E9 anonyme \u0022Exothera\u0022 dont le si\u00E8ge est situ\u00E9 en R\u00E9gion wallonne, Rue de la Maitrise 11 \u00E0 1400 Nivelles, avec le num\u00E9ro d\u0027entreprise 0744.643.660, il a \u00E9t\u00E9 d\u00E9cid\u00E9 \u00E0 l\u0027unanimit\u00E9 de transf\u00E9rer le si\u00E8ge de la soci\u00E9t\u00E9 \u00E0 l\u0027adresse suivant",
"region_changed": false,
"is_statute_change": false,
"nationality_change": false,
"old_address_source": "act_body",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "retroactive",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": "G\u00E9rard INDEKEU",
"firm_city": null,
"firm_name": null,
"office_city": "Nivelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2021-03-15",
"filing_date": "2021-03-05",
"act_kind_objet": "Objet de l\u0027acte: Transert du si\u00E8ge"
},
"decision": {
"body": "raad_van_bestuur",
"date": "2021-03-05",
"unanimous": true
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"Proces-verbal du conseil d\u0027administration",
"D\u00E9claration de transfert du si\u00E8ge"
]
}05-03-2021 Augmentation de capital de 7.000.000 € à 8.008.840 €
- €1.008.840 → €8.008.840
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 8008840.0,
"delta_eur": 7000000.0,
"before_eur": 1008840.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}13-10-2020 4 administrateurs nommés
- TheClubDeal SA — Bestuurder
- Cahn Consult BV — Bestuurder
- SAMANDA SA — Bestuurder
- BioPharma Management and Consulting — Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "TheClubDeal SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Cahn Consult BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "SAMANDA SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "BioPharma Management and Consulting",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}18-06-2020 Modification des statuts
Détails techniques
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": true
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 Anonyme",
"old": "Soci\u00E9t\u00E9 Anonyme",
"changed": false
}
}18-06-2020 Augmentation de capital de 947.340 € à 1.008.840 €
- €61.500 → €1.008.840
- Inbreng in natura · Apport en nature
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 1008840,
"delta_eur": 947340,
"before_eur": 61500,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA"
}
}24-03-2020 Publication au Moniteur belge — Divers
Détails techniques
{
"stage": "proposal",
"notary": {
"name": "Sixtine Borres",
"firm_city": null,
"firm_name": null,
"office_city": "Nivelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2020-03-24",
"filing_date": "2020-03-12",
"act_kind_objet": "DEPOT D\u0027UN PROJET COMMUN D\u0027APPORT D\u0027UNE BRANCHE D\u0027ACTIVITE"
},
"decision": {
"body": "raad_van_bestuur",
"act_date": "2020-03-12",
"unanimous": null
},
"conversion": null,
"detected_kind": "branch_contribution",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0502.742.288",
"name": "UNIVERCELLS SA",
"role": "contributor",
"address": "Rue Auguste Piccard 48, 6041 Charleroi",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0744.643.660",
"name": "EXOTHERA SA",
"role": "recipient",
"address": "Rue de la Ma\u00EEtrise 11, 1400 Nivelles",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"12:93"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "La branche d\u0027activit\u00E9 \u0027CDMO\u0027 de la soci\u00E9t\u00E9 UNIVERCELLS SA est transf\u00E9r\u00E9e \u00E0 EXOTHERA SA. Le transfert porte sur une activit\u00E9 sp\u00E9cifique, sans transfert du patrimoine global.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0744.643.660",
"name_full": "EXOTHERA",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Sixtine Borres",
"org_rep_person_name": null
},
"summary_narrative": "Le conseil d\u0027administration de UNIVERCELLS SA a d\u00E9cid\u00E9, le 12 mars 2020, de transf\u00E9rer sa branche d\u0027activit\u00E9 \u0027CDMO\u0027 \u00E0 EXOTHERA SA. Ce projet d\u0027apport est soumis \u00E0 d\u00E9p\u00F4t au greffe du Tribunal de l\u0027entreprise du Brabant wallon, avec d\u00E9signation de mandataires sp\u00E9ciaux pour signer les formulaires de d\u00E9p\u00F4t et de publication.",
"co_filed_documents": [],
"detected_real_type": "branch_contribution",
"referenced_correction": null,
"should_reroute_to_category": null
}04-03-2020 Constitution d'une société (SA)
Détails techniques
{
"notary": {
"name": "G\u00E9rard INDEKEU",
"firm_city": null,
"firm_name": "G\u00E9rard INDEKEU - Dimitri CLEENEWERCK de CRAYENCOUR",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2020-03-04",
"filing_date": "2020-03-02",
"act_kind_objet": "Objet de l\u0027acte:",
"is_private_deed": false
},
"decision": {
"body": "notarieel_alleen",
"act_date": "2020-02-28",
"unanimous": true
},
"founders": [
{
"org": {
"kbo": "0502.742.288",
"name": "UNIVERCELLS",
"address": "6041 Charleroi, Rue Auguste Piccard 48",
"country": "BE",
"legal_form": "SA",
"foreign_register_name": null,
"foreign_register_number": null
},
"kind": "rechtspersoon",
"person": null,
"share_class": null,
"partner_role": "null",
"contribution_type": "geld",
"amount_paid_in_eur": 61500.0,
"is_subscriber_only": false,
"n_shares_subscribed": 61500,
"amount_subscribed_eur": 61500.0,
"is_anonymous_silent_partner": false
}
],
"voorwerp": {
"full_text": "La soci\u00E9t\u00E9 a pour objet, en Belgique et \u00E0 l\u0027\u00E9tranger, soit directement, soit comme interm\u00E9diaire, tant pour son compte propre que pour le compte de tiers ce qui est pr\u00E9vu ci-apr\u00E8s : Favoriser le d\u00E9veloppement de la recherche m\u00E9dicale et biom\u00E9dicale au sens large en vue d\u2019\u00E9laborer et concevoir des produits de toute nature incluant des m\u00E9dicaments ou des techniques m\u00E9dicales, en vue de favoriser tous services, savoir faires ou syst\u00E8mes techniques, sociologiques, philosophiques, psychologiques pouvant contribuer, de mani\u00E8re innovante, \u00E0 la sant\u00E9 et/ou au bien-\u00EAtre de l\u2019homme dans le respect de l\u2019environnement. L\u2019\u00E9tude, le d\u00E9veloppement, la fabrication, le traitement, l\u2019importation et l\u2019exportation, l\u2019achat et la vente, la repr\u00E9sentation, la distribution et le commerce en g\u00E9n\u00E9ral de tous les produits pharmaceutiques et chimiques, outils, sp\u00E9cialis\u00E9s et accessoires, utilis\u00E9s en pharmacie, diagnostic, th\u00E9rapie, laboratoire ou m\u00E9decine en g\u00E9n\u00E9ral et \u00E9galement dans les h\u00F4pitaux et divers services de sant\u00E9. L\u2019utilisation, la recherche, le d\u00E9veloppement en ce compris l\u2019organisation de tests cliniques, l\u2019exploitation, la transformation, le conditionnement, la fabrication, la promotion, l\u2019achat et la commercialisation sous toutes ses formes de tous produits chimiques ou biologiques, de tous s\u00E9rums, vaccins, toxines et de tous produits, sous-produits ou d\u00E9riv\u00E9s d\u2019origine animale, v\u00E9g\u00E9tale, microbienne, pouvant servir sous une forme quelconque au diagnostic, \u00E0 la prophylaxie et \u00E0 la th\u00E9rapeutique des maladies humaines ou animales. La recherche et le d\u00E9veloppement, la promotion, l\u2019achat et la vente de tous produits pharmaceutiques, th\u00E9rapeutiques, cosm\u00E9tiques, di\u00E9t\u00E9tiques, \u00E0 usage humain, v\u00E9g\u00E9tal, animal, biologiques, produits chimiques, de tous mat\u00E9riels et instruments m\u00E9dicaux et chirurgicaux, et de mani\u00E8re g\u00E9n\u00E9rale, tous op\u00E9rations industrielles, commerciales, financi\u00E8res ou civiles se rapportant directement ou indirectement aux activit\u00E9s dans le domaine de l\u2019industrie biopharmaceutique. La soci\u00E9t\u00E9 peut r\u00E9aliser tous travaux et tout acte juridique qui sont de nature \u00E0 stimuler directement la r\u00E9alisation de son objet et notamment tout acte mobilier ou immobilier par rapport aux locaux m\u00E9dicaux, l\u2019achat et la vente du mat\u00E9riel m\u00E9dical et non-m\u00E9dical, le recrutement du personnel administratif ou soignant, en service dans la soci\u00E9t\u00E9. Elle ne peut cependant pas faire des actes qui sont contradictoires aux r\u00E8gles de la d\u00E9ontologie m\u00E9dicale. Elle peut constituer, d\u00E9velopper et g\u00E9rer un patrimoine mobilier et faire toutes op\u00E9rations mobili\u00E8res quelconques y compris celles se rapportant \u00E0 tous droits mobiliers comme l\u0027acquisition par voie d\u0027inscription ou de cession et la gestion d\u0027actions, de parts sociales, d\u0027obligations convertibles ou non, de pr\u00EAts de consommation, de pr\u00EAts ordinaires, de bons de caisse ou autres valeurs mobili\u00E8res, de quelque forme que ce soit, tant de personnes morales que d\u0027entreprises, belges ou \u00E9trang\u00E8res, existantes ou encore \u00E0 constituer. La soci\u00E9t\u00E9 pourra exercer tout mandat g\u00E9n\u00E9ralement quelconque ainsi que toute fonction autoris\u00E9e dans toute personne morale belge ou \u00E9trang\u00E8re en ce compris la fonction d\u2019administrateur, de d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re, de g\u00E9rant et de liquidateur. Ce mandat pourra \u00EAtre r\u00E9mun\u00E9r\u00E9 ou gratuit. La soci\u00E9t\u00E9 peut, par voie d\u0027apport en esp\u00E8ces ou en nature, de fusion, de souscription, de participation, d\u0027intervention financi\u00E8re ou autrement, prendre des participations dans d\u0027autres soci\u00E9t\u00E9s ou entreprises existantes ou \u00E0 cr\u00E9er, que ce soit en Belgique ou \u00E0 l\u0027\u00E9tranger, dont l\u0027objet serait semblable ou analogue au sien ou de nature \u00E0 favoriser son objet. Elle peut \u00E9galement consentir tous pr\u00EAts ou garantir tous pr\u00EAts consentis par des tiers, \u00E9tant entendu que la soci\u00E9t\u00E9 n\u0027effectuera aucune activit\u00E9 dont l\u2019exercice serait soumis \u00E0 des dispositions l\u00E9gales ou r\u00E9glementaires applicables aux \u00E9tablissements de cr\u00E9dits et/ou financiers. Elle peut faire toutes op\u00E9rations se rapportant directement ou indirectement au management en g\u00E9n\u00E9ral, et plus pr\u00E9cis\u00E9ment, sans que cette \u00E9num\u00E9ration ne soit limitative : la cr\u00E9ation de soci\u00E9t\u00E9s holding ou d\u0027exploitation, toutes activit\u00E9s d\u0027\u00E9tudes et de conseils, toutes prestations de services, tous travaux d\u0027administration, de gestion, tant aupr\u00E8s des entreprises que des particuliers. Elle peut octroyer des conseils et assister en toutes mati\u00E8res \u00E0 des entreprises et \u00E0 l\u2019administration et la gestion d\u2019entreprises. Elle peut faire toutes op\u00E9rations commerciales, industrielles et financi\u00E8res, immobili\u00E8res et mobili\u00E8res, se rapportant directement ou indirectement \u00E0 son objet ou susceptibles de favoriser son d\u00E9veloppement, \u00E0 l\u0027exception des op\u00E9rations sur valeurs mobili\u00E8res et immobili\u00E8res r\u00E9serv\u00E9es par la loi aux banques et aux soci\u00E9t\u00E9s de bourse. Elle peut constituer, d\u00E9velopper, promouvoir et g\u00E9rer un patrimoine immobilier, et r\u00E9aliser toute op\u00E9ration immobili\u00E8re et fonci\u00E8re quelconque, y compris celles se rapportant \u00E0 tous droits r\u00E9els immobil",
"is_lucrative": true,
"short_summary": "Recherche, d\u00E9veloppement, fabrication, commercialisation et distribution de produits pharmaceutiques, biologiques, m\u00E9dicaux, cosm\u00E9tiques, di\u00E9t\u00E9tiques et chimiques, ainsi que gestion de patrimoines mobiliers et immobiliers."
},
"governance": {
"organ_kind": "raad_van_bestuur",
"n_directors_max": null,
"n_directors_min": 2,
"representation_clause": "deux administrateurs conjointement ou un administrateur-d\u00E9l\u00E9gu\u00E9 seul",
"co_signature_threshold_eur": null
},
"fiscal_year": {
"end_mm_dd": "12-31",
"start_mm_dd": "01-01",
"first_exercise_end_date": "2020-12-31",
"is_prolonged_first_exercise": false
},
"agm_schedule": {
"time": "18:30",
"month": 6,
"rule_text": "troisi\u00E8me jeudi de juin"
},
"founding_event": {
"n_shares_total": 61500,
"n_share_classes": 1,
"bank_attestation": null,
"amount_paid_in_eur": 61500.0,
"incorporation_date": "2020-02-28",
"amount_subscribed_eur": 61500.0,
"art_5_8_no_payment_due": false,
"pre_incorporation_activity_from_date": null
},
"subject_company": {
"kbo": "0744.643.660",
"email": null,
"region": "waals_gewest",
"website": null,
"name_full": "EXOTHERA",
"legal_form": "SA",
"name_abbreviated": null,
"zetel_address_raw": "Rue de la Ma\u00EEtrise 11, 1400 Nivelles",
"equity_account_type": "unavailable",
"_kbo_filled_from_list": true
},
"initial_directors": [
{
"kind": "natural_person",
"person": {
"name": "Hugues BULTOT",
"address": "1150 Woluwe-Saint-Pierre, Avenue de l\u0027Horizon 24"
},
"via_org": null,
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2026
},
"rep_person_name": null,
"additional_roles": [
"administrateur-d\u00E9l\u00E9gu\u00E9"
],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": null
},
{
"kind": "natural_person",
"person": {
"name": "Jos\u00E9 CASTILLO",
"address": "1000 Bruxelles, Rue de la Buanderie 18 bo\u00EEte b3.1"
},
"via_org": null,
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2026
},
"rep_person_name": null,
"additional_roles": [
"pr\u00E9sident du conseil d\u0027administration"
],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": null
}
],
"co_filed_documents": [
"expedition",
"statuten",
"volmacht"
],
"post_incorporation_mandates": [
{
"kind": "volmacht_kbo",
"holder_org_kbo": null,
"holder_org_name": "PwC Legal",
"with_substitution": true,
"holder_person_name": null
}
]
}Générez une note structurée et factuelle à partir de tous les signaux de ce dossier : risque, santé financière, structure de propriété, mandats et comparaison sectorielle.
| Dénomination légaleFR | EXOTHERA |